泰国使用潜在下一代流感疫苗接种的健康影响和成本效益:一项模拟研究。

IF 7.1 2区 医学 Q1 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH BMJ Global Health Pub Date : 2024-11-18 DOI:10.1136/bmjgh-2024-015837
Simon R Procter, Naomi R Waterlow, Sreejith Radhakrishnan, Edwin van Leeuwen, Aronrag Meeyai, Ben S Cooper, Sunate Chuenkitmongkol, Yot Teerawattananon, Rosalind M Eggo, Mark Jit
{"title":"泰国使用潜在下一代流感疫苗接种的健康影响和成本效益:一项模拟研究。","authors":"Simon R Procter, Naomi R Waterlow, Sreejith Radhakrishnan, Edwin van Leeuwen, Aronrag Meeyai, Ben S Cooper, Sunate Chuenkitmongkol, Yot Teerawattananon, Rosalind M Eggo, Mark Jit","doi":"10.1136/bmjgh-2024-015837","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Thailand was one of the first low- and middle-income countries to publicly fund seasonal influenza vaccines, but the lack of predictability in the timing of epidemics and difficulty in predicting the dominant influenza subtypes present a challenge for existing vaccines. Next-generation influenza vaccines (NGIVs) are being developed with the dual aims of broadening the strain coverage and conferring longer-lasting immunity. However, there are no economic evaluations of NGIVs in Thailand.</p><p><strong>Methods: </strong>We estimated the health impact and cost-effectiveness of NGIVs in Thailand between 2005 and 2009 using a combined epidemiological and economic model. We fitted the model to data on laboratory-confirmed influenza cases and then simulated the number of influenza infections, symptomatic cases, hospitalisations and deaths under different vaccination scenarios based on WHO-preferred product characteristics for NGIVs. We used previous estimates of costs and disability adjusted life years (DALYs) for influenza health outcomes to estimate incremental net monetary benefit, vaccine threshold prices and budget impact.</p><p><strong>Results: </strong>With the current vaccine programme, there were an estimated 61 million influenza infections. Increasing coverage to 50% using improved vaccines reduced infections to between 23 and 57 million, and with universal vaccines to between 21 and 49 million, depending on the age groups targeted. Depending on the comparator, threshold prices for NGIVs ranged from US$2.80 to US$12.90 per dose for minimally improved vaccines and US$24.60 to US$69.90 for universal vaccines.</p><p><strong>Conclusion: </strong>Influenza immunisation programmes using NGIVs are anticipated to provide considerable health benefits and be cost-effective in Thailand. However, although NGIVs might even be cost-saving in the long run, there could be significant budget implications for the Thai government even if the vaccines can be procured at a substantial discount to the maximum threshold price.</p>","PeriodicalId":9137,"journal":{"name":"BMJ Global Health","volume":"9 11","pages":""},"PeriodicalIF":7.1000,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11574519/pdf/","citationCount":"0","resultStr":"{\"title\":\"Health impact and cost-effectiveness of vaccination using potential next-generation influenza vaccines in Thailand: a modelling study.\",\"authors\":\"Simon R Procter, Naomi R Waterlow, Sreejith Radhakrishnan, Edwin van Leeuwen, Aronrag Meeyai, Ben S Cooper, Sunate Chuenkitmongkol, Yot Teerawattananon, Rosalind M Eggo, Mark Jit\",\"doi\":\"10.1136/bmjgh-2024-015837\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Thailand was one of the first low- and middle-income countries to publicly fund seasonal influenza vaccines, but the lack of predictability in the timing of epidemics and difficulty in predicting the dominant influenza subtypes present a challenge for existing vaccines. Next-generation influenza vaccines (NGIVs) are being developed with the dual aims of broadening the strain coverage and conferring longer-lasting immunity. However, there are no economic evaluations of NGIVs in Thailand.</p><p><strong>Methods: </strong>We estimated the health impact and cost-effectiveness of NGIVs in Thailand between 2005 and 2009 using a combined epidemiological and economic model. We fitted the model to data on laboratory-confirmed influenza cases and then simulated the number of influenza infections, symptomatic cases, hospitalisations and deaths under different vaccination scenarios based on WHO-preferred product characteristics for NGIVs. We used previous estimates of costs and disability adjusted life years (DALYs) for influenza health outcomes to estimate incremental net monetary benefit, vaccine threshold prices and budget impact.</p><p><strong>Results: </strong>With the current vaccine programme, there were an estimated 61 million influenza infections. Increasing coverage to 50% using improved vaccines reduced infections to between 23 and 57 million, and with universal vaccines to between 21 and 49 million, depending on the age groups targeted. Depending on the comparator, threshold prices for NGIVs ranged from US$2.80 to US$12.90 per dose for minimally improved vaccines and US$24.60 to US$69.90 for universal vaccines.</p><p><strong>Conclusion: </strong>Influenza immunisation programmes using NGIVs are anticipated to provide considerable health benefits and be cost-effective in Thailand. However, although NGIVs might even be cost-saving in the long run, there could be significant budget implications for the Thai government even if the vaccines can be procured at a substantial discount to the maximum threshold price.</p>\",\"PeriodicalId\":9137,\"journal\":{\"name\":\"BMJ Global Health\",\"volume\":\"9 11\",\"pages\":\"\"},\"PeriodicalIF\":7.1000,\"publicationDate\":\"2024-11-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11574519/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMJ Global Health\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1136/bmjgh-2024-015837\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ Global Health","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/bmjgh-2024-015837","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0

摘要

导言:泰国是首批公共资助季节性流感疫苗的中低收入国家之一,但流行时间缺乏可预测性以及难以预测主要流感亚型给现有疫苗带来了挑战。目前正在开发新一代流感疫苗 (NGIV),以实现扩大菌株覆盖范围和延长免疫力的双重目标。然而,泰国尚未对 NGIV 进行经济评估:方法:我们使用流行病学和经济学相结合的模型估算了 2005 年至 2009 年 NGIVs 在泰国的健康影响和成本效益。我们将该模型与实验室确诊的流感病例数据相匹配,然后根据世界卫生组织推荐的 NGIV 产品特性,模拟了不同疫苗接种方案下的流感感染人数、有症状病例数、住院人数和死亡人数。我们利用以前对流感健康结果的成本和残疾调整生命年(DALYs)的估算来估算增量净货币效益、疫苗临界价格和预算影响:结果:在目前的疫苗计划下,估计有 6100 万人感染了流感。使用改良疫苗将覆盖率提高到 50%,感染人数将减少到 2,300 万至 5,700 万,而使用通用疫苗则将感染人数减少到 2,100 万至 4,900 万,这取决于目标年龄组。根据比较对象的不同,最低改良疫苗的 NGIV 临界价格从每剂 2.80 美元到 12.90 美元不等,通用疫苗的临界价格从 24.60 美元到 69.90 美元不等:结论:在泰国,使用 NGIV 的流感免疫接种计划预计将带来可观的健康效益和成本效益。然而,尽管从长远来看 NGIV 甚至可以节约成本,但即使能够以低于最高阈值价格的大幅折扣采购疫苗,也可能会对泰国政府的预算产生重大影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Health impact and cost-effectiveness of vaccination using potential next-generation influenza vaccines in Thailand: a modelling study.

Introduction: Thailand was one of the first low- and middle-income countries to publicly fund seasonal influenza vaccines, but the lack of predictability in the timing of epidemics and difficulty in predicting the dominant influenza subtypes present a challenge for existing vaccines. Next-generation influenza vaccines (NGIVs) are being developed with the dual aims of broadening the strain coverage and conferring longer-lasting immunity. However, there are no economic evaluations of NGIVs in Thailand.

Methods: We estimated the health impact and cost-effectiveness of NGIVs in Thailand between 2005 and 2009 using a combined epidemiological and economic model. We fitted the model to data on laboratory-confirmed influenza cases and then simulated the number of influenza infections, symptomatic cases, hospitalisations and deaths under different vaccination scenarios based on WHO-preferred product characteristics for NGIVs. We used previous estimates of costs and disability adjusted life years (DALYs) for influenza health outcomes to estimate incremental net monetary benefit, vaccine threshold prices and budget impact.

Results: With the current vaccine programme, there were an estimated 61 million influenza infections. Increasing coverage to 50% using improved vaccines reduced infections to between 23 and 57 million, and with universal vaccines to between 21 and 49 million, depending on the age groups targeted. Depending on the comparator, threshold prices for NGIVs ranged from US$2.80 to US$12.90 per dose for minimally improved vaccines and US$24.60 to US$69.90 for universal vaccines.

Conclusion: Influenza immunisation programmes using NGIVs are anticipated to provide considerable health benefits and be cost-effective in Thailand. However, although NGIVs might even be cost-saving in the long run, there could be significant budget implications for the Thai government even if the vaccines can be procured at a substantial discount to the maximum threshold price.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
BMJ Global Health
BMJ Global Health Medicine-Health Policy
CiteScore
11.40
自引率
4.90%
发文量
429
审稿时长
18 weeks
期刊介绍: BMJ Global Health is an online Open Access journal from BMJ that focuses on publishing high-quality peer-reviewed content pertinent to individuals engaged in global health, including policy makers, funders, researchers, clinicians, and frontline healthcare workers. The journal encompasses all facets of global health, with a special emphasis on submissions addressing underfunded areas such as non-communicable diseases (NCDs). It welcomes research across all study phases and designs, from study protocols to phase I trials to meta-analyses, including small or specialized studies. The journal also encourages opinionated discussions on controversial topics.
期刊最新文献
Global development assistance for early childhood care and education in 134 low- and middle-income countries, 2007-2021. Data for whom? Experiences and perceptions of a perinatal eRegistry in two hospitals in Mtwara region, Tanzania. Caught between violence: Mpox virus and the perils of neglect in Africa. Health impact and cost-effectiveness of vaccination using potential next-generation influenza vaccines in Thailand: a modelling study. Probing the past: historical case study analysis to inform more just and sustainable global health partnerships in education.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1